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Objectives: Uterine fibroids (UF) are the most common benign tumors of the female 
reproductive organ. It is crucial to recognize that the appropriate treatment of UFs requires an 
individualized approach. The present paper aimed at the presentation of the five-year 
experience of our center in the treatment of UFs with the use of magnetic resonance-guided 
high-intensity ultrasound (MR-HIFU) therapy. 
Material and methods: The study enrolled a total of 1284 patients with symptomatic UFs. 
The Sonalleve MR-HIFU system (Philips Ingenia 3.0T System) was used for magnetic 
resonance imaging (MRI) qualification and treatment. 
Results: The group of patients qualified for thermal ablation included 356 (28%) women. No 
significant differences were observed between the group undergoing thermal ablation and 
patients who were disqualified. A complete procedure was performed in 22.6% of patients 
who presented at the center. Non-perfused volume (NPV) is one of the most important 
parameters assessed during MR-HIFU procedures. The mean NPV value in the present study 
was 71%. The average UF volumes decreased by 27% at three-month follow-up ultrasound, 
by 34% after six months and by 39% as shown by MRI measurements performed 6 months 
post-treatment. 
Conclusions: According to our data, MR-HIFU therapy is associated with good clinical 
outcomes in patients with symptomatic UFs. The method facilitates a marked symptom 
reduction and, in many cases, diminishing tumor volume. The presented five-year outcomes 
as regards our experience in the MR-HIFU therapy of patients with symptomatic UFs indicate 
that the method offers an attractive alternative to the traditional methods of UF treatment in 
selected cases. 
Key words: uterine fibroid; leiomyoma; non-invasive; magnetic resonance imaging; 
magnetic resonance-guided high-intensity ultrasound; MR-HIFU 
 
Introduction 
Uterine fibroids (UF) are the most common benign tumors of the female reproductive 
organ [1]. They constitute the most common reason for hysterectomy worldwide [2]. 
Therefore, the pathology should be regarded as a major socioeconomic problem of the 
healthcare system [3, 4]. In some populations UFs are thought to occur in as many as 60–70% 
of women [5]. The lesions are symptomatic in approximately 30–50% of cases triggering the 
following manifestations: menorrhagia, anemia, dyspareunia, pelvic pain, psychological 
disorders, and pregnancy complications including fertility disorders, miscarriage or premature 
delivery [6]. The peak incidence is observed between 40 and 50 years of age, with the number 
of new cases decreasing after menopause and the symptoms resolving over time in many 
cases [7]. The reasons for the development of UFs have not been fully elucidated. It is 
currently known that they develop by means of the conversion of a normal myometrial cell 
into a monoclonal tumor. Steroid hormones, progesterone in particular, are considered to play 
an essential role in promoting the formation and growth of those tumors [1, 8]. However, 
hormones are not the only factors influencing those pathophysiological pathways [9, 10]. UF 
development is also largely dependent on genetic factors [11, 12], with the disruption of DNA 
repair mechanisms also playing a role [13]. UFs are markedly more common in dark-skinned 
women, e.g., African Americans, compared to white women [5, 14]. It is necessary to act 
because, even in populations characterized by a lower UF incidence their occurrence seems to 
become higher [15]. Therefore, research is constantly conducted into new possible risk factors 
[16, 17] and the development of new strategies of prophylaxis and treatment [18, 19]. 
It is crucial to recognize that the appropriate treatment of UFs requires an 
individualized, patient-tailored approach and is dependent on patient's age, tumor location and 
size, symptoms and the expectations of the patient concerning reproductive plans [20, 21]. 
Currently, numerous modalities are implemented, including conservative treatment, less 
invasive, but still highly effective methods of invasive radiology [e.g., uterine artery 
embolization (UAE)], and surgery, which may include endoscopic procedures, classic uterus-
sparing surgeries, and partial or complete hysterectomies [6, 21–23].  
Conservative treatment with the use of antihemorrhagic tablets, contraceptive pills or 
intrauterine devices only aims at relieving the symptoms and is often associated with poor 
effectiveness [18]. Pharmacological modalities in UF treatment, e.g., ulipristal acetate [24], or 
oral gonadotropin-releasing hormone (GnRH) analogues [25] are easy as regards the 
administration and effective in the reduction of symptoms. However, the use of those drugs 
may be perceived as problematic, as they also influence other aspects, e.g., by triggering 
climacteric symptoms [26, 27], or causing dangerous adverse events [28]. Therefore, 
regrettably, anti-fibroid drugs are not used for long-term treatment, but rather as preoperative 
preparation [29]. Some scientific societies specified the guidelines for the treatment of UFs, 
e.g., the recommendations of the Society of Obstetricians and Gynaecologists of Canada 
(SOGC) published in 2015 [21]. The algorithm for the management of UFs mostly covered 
the available methods of treatment and is up-to-date even as regards the issue of selective 
progesterone receptor modulators, whose use requires further clarification [25, 28]. Some 
hopes are attached to new oral gonadotropin-releasing hormone antagonists that are already 
available in Western markets [27]. 
According to recent analyses, non-surgical methods may lead to positive effects which 
are similar to those of myomectomy in various aspects. In regards those methods — the 
treatment effectiveness of uterine artery embolization (UAE) was confirmed to the largest 
extent [30]. Some authors suggested that UAE was a safe and effective mini-invasive 
treatment modality for symptomatic UFs [21, 31]. The additional advantage of this method is 
related to the fact that despite changing the clinical symptoms it also significantly reduces UF 
volume (especially in larger lesions) [32]. Notably, Poland has considerable experience in this 
therapy and sets global standards, e.g. via the development of specialist uniform, protocol for 
clinicians performing UAE (Lublin Protocol) [33]. 
However, this paper focuses on a different method — high-intensity ultrasound 
(HIFU), which is frequently described together with UAE. It is due to the fact that both 
methods are relatively new compared to those known for many years [34]. UF treatment with 
HIFU involves the precise concentration of high-intensity ultrasound waves on the tumor 
focus. In such a case the blood vessels are not blocked and the energy of ultrasound increases 
the temperature and, thereby, destroys the tissue via ablation [34]. Currently, two types of 
systems are integrated with HIFU, with one being magnetic resonance-guided (MRI) and the 
other ultrasound-guided. Differences may be substantial, particularly depending on a specific 
device and the expertise of the personnel, but the principle of the procedure is rather similar. 
Both methods have their proponents and opponents. The example of ultrasound-guided 
procedures performed in breast cancer shows that they are inexpensive and convenient and 
may be performed in real-time, whereas MR-HIFU can provide supreme-resolution images 
and better thermometry data [35]. In the case of our center, because of the equipment 
available, we present high-intensity thermal ablation performed with MR-HIFU device. In 
this technique, a radiologist controls the transducer of an MRI device to target a focused beam 
of ultrasound at a small area of a UF, and, step by step, the temperature of the tissue is 
increased leading to protein denaturation and necrosis (Fig. 1). Real-time temperature 
mapping in the target tissue and adjacent tissues is performed with magnetic resonance during 
the whole procedure. The procedure is characterized by high precision and is performed 
completely on an outpatient basis. Pro-Familia Specialized Hospital in Rzeszów was one of 




The present paper aimed at the presentation of the five-year experience of our center in 
the treatment of UFs with the use of MR-HIFU therapy. The main aims of this study include 
the assessment of the effectiveness, success rate, patient satisfaction and symptom resolution, 
as well as introducing this method to wider audience. 
 
MATERIAL AND METHODS  
The study group included women with symptomatic UFs treated in Pro-Familia 
Specialized Hospital in Rzeszów. The study was approved by the Local Bioethics Committee 
of the Regional Medical Chamber in Rzeszów (approval no. 1/B/2015, 22/B/2015, 35/B/2015, 
38/B/2015).  
Patient qualification for the study involved: a gynecological clinical examination, MRI 
assessment followed by thermal ablation with the simultaneous determination of the 
effectiveness of the procedure. The whole procedure (despite some exceptions) was 
performed completely on an outpatient basis. The patients were admitted after an overnight 
fast following several days of consuming an easily digestible diet. A follow-up gynecological 
visit was conducted about three months after the procedure. It involved completing a basic 
questionnaire to assess the quality of life (QoL). The symptoms might be assessed by the 
patients on a simplified 5-point Likert-type scale: 1 — ‘much worse’; 2 — ‘worse’; 3 — ‘the 
same’; 4 — ‘better’; 5 — ‘much better’. The aim of using the scale was to indicate the 
subjective perception of the above presented symptoms after the procedure. The researchers 
had assumed that the scale should be as simple as possible in order not to discourage the 
patients and obtain the highest possible follow-up rate. A six-month follow-up consisted in 
basic QoL assessment (as above) and undergoing a gynecological examination and a control 
MRI.    
The Sonalleve MR-HIFU system (Philips Ingenia 3.0T System) was used for MRI 
qualification and treatment. Due to economic reasons, control MRI was only performed in the 
patients whose baseline non-perfused volume (NPV) was ≥ 70%. The study enrolled a total of 
1284 patients who presented at the hospital in order to be qualified for ultrasound thermal 
ablation. The inclusion criteria were a single lesion, UF symptoms, such as menorrhagia, 
abdominal pain, dyspareunia, and, because of grant requirements, inability to conceive, tumor 
size > 2 cm. In regards to the grant, the qualification criteria between the years 2015 and 2018 
included a symptomatic UF, inability to conceive with the exclusion of other factors 
impairing fertility, a history of miscarriage, a positive MRI qualification of the UF type 
according to a classification by Funaki et al. (2007) [36]. In 2018–2020, after completing the 
research covered by the first grant, we enlarged the study group to women aged until 50 and 
disregarded the issue of infertility. We considered the cases of symptomatic UFs manifesting 
as abdominal pain, menorrhagia and dysmenorrhea, intermenstrual bleeding, and other UF-
related symptoms. The exclusion criteria for the whole study period were: contraindications 
for MRI procedures or contrast administration, an active inflammation of the minor pelvic 
cavity, the diagnosis of an adnexal tumor, asymptomatic lesions, tumor size > 13 cm, Funaki 
type III UFs [36], the excess of the adipose tissue (distance between the posterior margin of 
the UF and the skin surface of > 13 cm).   
During the procedure, the patients were lying in a prone position on a special gel pad. 
Subsequently, three lines were determined along which the temperature was monitored: 
passing through the center of the UF, on the skin surface (so called ‘proximal surface’) and 
beyond the lesion (so called ‘distal surface’). Another step involved the determination of the 
predicted thermal dose volume (PTV) of the UF via delineating its external outline. Then, so 
called ‘therapeutic cells/volumes’ were determined as the targets of the energy of the 
ultrasound. The ultrasound wave was adjusted during the sonication of each cell/volume as 
regards the frequency (1.2 MHz or 1.4 MHz) and power (maximum: 500 Watt). MRI-derived 
real-time temperature maps facilitated the monitoring of the local distribution of heat to adjust 
its value to approx. 55-65 degrees Celsius. The patients were administered a contrast agent 
intravenously (0.1 mmol/kg Gd-DO3A-butrol, Gadovist; Bayer Schering Pharma) and the 
degree of ablation was determined by measuring NPV during the qualifying examination and 




The study enrolled a total of 1284 patients with symptomatic UFs. A total of 1048 
MRI tests were performed. Upon gynecological examination, 235 (25%) cases were 
disqualified. The group of patients qualified for thermal ablation included 356 (28%) women. 
Pain, stress and impatience of some women, no reaction of the UF tissue to ultrasound were 
the reasons for the discontinuation of 68 procedures. Therefore, a complete MR-HIFU 
procedure was performed in 22.6% of patients who presented at our center (Tab. 1). 
 













































MRI — magnetic resonance imaging; MR-HIFU — magnetic resonance-guided high-
intensity ultrasound 
 
Throughout the study we obtained the abundance of epidemiological data concerning 
women seeking alternative methods of UF therapy. The mean age of study group patients was 
36.6 years and the average body mass index (BMI) equaled 23.5 kg/m2. No significant 
differences were observed between the group undergoing MR-HIFU procedure and patients 
who were disqualified. The data are presented in Table 2. 
 
Table 2. Age and body mass index in the analyzed groups of patients 
 
Mean Median Minimum Maximum SD 
All patients       
Age [n] 36.6 37 19 58 5.3 
BMI [kg/m2] 23.5 22.5 15.8 60.5 4.3 
MR-HIFU  
not performed      
Age [n] 36.7 37 20 58 5.4 
BMI [kg/m2] 23.6 22.4 16.0 60.5 4.6 
MR-HIFU 
performed      
Age [n] 36.2 37 19 51 5.2 
BMI [kg/m2] 23.3 22.6 15.8 39.3 3.7 
BMI — body mass index; MR-HIFU — magnetic resonance-guided high-intensity 
ultrasound; SD — standard deviation 
 
We also analyzed the groups in terms of the most common symptoms, related to UFs. 
As shown in Table 3, the distribution of individual manifestations was similar in both groups. 
The manifestations were mostly associated with UF volume, while the age of patients was 
correlated with pain and voiding symptoms. The NPV value and UF volume reduction were 
associated with diminishing all groups of symptoms except voiding and gastrointestinal 
issues.  
 


















Menorrhagia   262 0.01
82 
0.0234 0.0090 
Pelvic pain  101 ns 0.0000 0.001 
Voiding issues 179 0.00
07 
0.0338 ns 





57 ns ns ns 
MR-HIFU — magnetic resonance-guided high-intensity ultrasound; NPV — non-perfused 
volume 
  
Subsequently, the groups were analyzed as regards the volume of UFs assessed both 
with an ultrasound or MRI examination. A statistically significant correlation was 
demonstrated between the groups: p = 0.0165 and p = 0.0092, respectively. The data were 
presented in Figure 2.   
NPV is one of the most important parameters assessed during MR-HIFU procedures.  
The mean NPV value in the present study was 71%. Moreover, it is worth noting that the 
parameter significantly improved in 2017–2020 in our center and currently it may even reach 
80%. The learning curve of the radiologist and the use of additional medications (e.g. 
oxytocin or misoprostol) are also of importance, as they may influence the effectiveness of the 
treatment  [37]. The mean duration of the procedure (sonication time) was 107 minutes and 
depended on the respective baseline UF volume. Correlation factor was r = 0.57, p = 0.00001. 
Admission to the department, preparation (positioning, test MRI scans) took the average of 65 
minutes.   
Another parameter assessed post-treatment was the change of UF volume at the three 
and six-month follow-up ultrasound tests and six-month follow-up MRI. The average UF 
volumes decreased by 27% at three-month follow-up ultrasound, by 34% after six months and 
by 39% as shown by MRI measurements performed 6 months post-treatment. The results are 
presented in Figure 3.   
Most studies and numerous researchers claimed that the main aim of the procedure 
targeting UFs was not the volume reduction, but alleviating UF-related symptoms (Ikink 
2013). Therefore, the present study also involved the assessment of patients’ opinions 
regarding the improvement of the QoL compared to the time prior to the procedure. The 
patients self-assessed the change in the QoL during the follow-up visits at three and six 
months. A basic non-validated questionnaire of symptom reduction and well-being assessment 
was developed by the authors for the needs of rapid clinical assessment for clinical procedures 
and the study. The patients completed the questionnaire during qualification and after 3 and 6 
months following the procedure. The questions tackled the following issues: pain, bleeding, 
voiding and gastrointestinal symptoms linked to UFs and well-being after the procedure. The 
improved QoL regarding the occurrence of UF-related symptoms was reported by 69% of 
women at three months and by 76% at six months post-treatment. Individual symptoms 
subsided in the patients depending on NPV and UF volume reduction. The data are presented 
in Figure 4.  
During the study period adverse events were reported in 12 patients. One patient had 
two or more symptoms. Six of those patients were hospitalized until the next post-procedure 
day. A detailed list of adverse events in those patients is presented in Table 4.  
 






Low-grade fever Hematuria Panic 
(claustrophobia) 
12 7 8 1 1 
 
Our previous publication included a report of initial experience concerning 
pregnancies in patients who had undergone MR-HIFU in our center [38]. The current number 
of reported pregnancies and healthy neonates delivered from those pregnancies is higher 
compared to the previously presented data.  
 
DISCUSSION 
The ultrasound thermal ablation of UFs guided by various tools (MRI, ultrasound) is 
an alternative to well-established therapies. However, it is not widely used due to the high 
cost of the procedure and no reimbursement in the majority of countries apart from Canada, 
Israel, Germany and, recently, Italy [39]. Another reason why the procedure is not common is 
the lack of appropriate cooperation between gynecologists and interventional radiologists. 
Operative treatment is still preferred by gynecologists, so surgery is the most common 
modality in the treatment of symptomatic UFs [2, 22]. In our viewpoint, some assumptions 
should be slightly changed, at least in terms of selected indications due to the most recent data 
concerning non-invasive treatment of UFs. An increasing number of studies, including those 
conducted in our center demonstrated that ultrasound thermal ablation was justified in women 
who wished to preserve fertility [38, 40, 41]. Obviously, it needs to be mentioned that, to the 
best of our knowledge, no current guidelines propose this method as safe in patients with 
reproductive plans or treated due to infertility. Nevertheless, a variety of opinions concerning 
this issue were presented, e.g., with reference to surgery. Therefore, the topic requires a 
highly individualized approach [42]. The hypothesis that prophylactic UF removal increases 
the probability of conceiving has not been confirmed by relevant research [42]. However, it is 
false in case of submucosal or intramural lesions which exert visible pressure on the line of 
the endometrium (uterine cavity deformity) as they may affect fertility to some extent. UF 
treatment should be considered in women in whom other reasons for infertility or 
miscarriages (infections, uterine defects, and disrupted ovulation) were gradually ruled out 
[42, 43]. In case of such tumors, and, particularly, if an endoscopic procedure may be 
hindered, we suggest considering the performance of an MR-HIFU procedure as a relatively 
safe and low-risk alternative [38]. Available research showed a relatively low risk associated 
with the procedures. Some authors suggested that adverse events related to ultrasound UF 
ablation under conscious sedation are mostly mild and temporary [44]. For example, a study 
by Liu et al. (2018) performed in 27,053 patients with benign uterine diseases revealed that 
major adverse events occurred in about 0.3844% of them. Those major events included 
mostly skin burn, leg pain, vaginal discharge or bleeding, urinary retention, acute cystitis, an 
intrauterine infection, bowel injury, kidney failure, thrombosis, pubic symphysis injury, or 
sciatic nerve injury [45]. Regardless of the low-risk or high-effectiveness aspects, in cases 
with no appreciable effect obtained MR-HIFU does not rule out the possibility of a definitive 
surgery in the future. 
According to the presented data, only 288 out of 1288 women underwent MR-HIFU. 
The presented therapy is known to be very expensive and the limitations concerning the 
patients are marked. Numerous factors may contribute to patient disqualification from the 
procedure, including tumor size, UF type and location, anatomic relations within the 
abdominal cavity, the presence of adhesions [46]. Nevertheless, factors which would have 
ruled out the procedure several years before (e.g. reproductive plans) might currently, or in 
the nearest future, be the indications for the therapy, depending on the manifestations and 
other clinical issues [47]. 
The mean age of presented patients equaled 36.6 years, which stays in line with the 
general epidemiology of UFs and the peak incidence reported in available literature [5]. 
However, in case of our center the age was mainly determined by the grant-related 
requirements, including the analysis of female fertility following thermal ablation and a 
comparison with patients who had undergone myomectomy. Between the years 2015 and 
2018 we only qualified symptomatic women at the maximum age of 43 considering the wish 
to conceive. As shown above, BMI in the group treated with MR-HIFU was 23.3 kg/m2, and 
in the women disqualified after MRI it was 23.6 kg/m2. In this place we should underline that 
body weight is linked to thermal ablation treatment, because the longer the distance to the 
lesion, the higher the chance of disqualifying the patient or achieving the unsatisfying 
effectiveness of the procedure. Importantly, the distance between the posterior margin of the 
UF and skin surface should not exceed 13 cm. It also refers to adipose tissue thickness over 3 
cm, due to the high absorption of ultrasound energy. Therefore, not all patients, especially 
those considerably obese, may be offered treatment with this method. The care of obese UF-
positive patients is always more difficult compared to patients with normal body weight [48]. 
The present group included some women who had been initially disqualified, and later they 
were successfully treated with MR-HIFU. This study revealed no differences in BMI between 
the groups with regard to the correlation between markedly increased body weight and the 
occurrence of UFs [49]. The measurements were obviously random in some manner, targeted 
at a specific group. The inclusion and exclusion criteria of the grant also had an influence on 
the obtained results. Therefore, they should not be assessed in terms of the whole population 
and should be carefully extrapolated on other comparable populations.  
It needs to be emphasized again that MR-HIFU is a non-invasive procedure which 
may be performed on an outpatient basis [50]. MR-HIFU is highly advantageous over 
myomectomy or hysterectomy which frequently require hospitalization. Except for several 
cases, the patients were discharged home and returned to work shortly after the procedure. 
When performing a detailed comparison of the cost of MR-HIFU and surgeries it should 
obviously be considered that surgeries, even endoscopic ones, necessitate a hospital stay 
which may last several days, and the risk of complications typical of operative treatment is 
higher, which additionally increases the cost if they occur. Moreover, patients undergoing 
conventional treatment frequently must remain on sick leave, which is of high 
macroeconomic significance [3]. Another problem associated with MR-HIFU is the price of 
the device, the cost of personnel training and the cost of the procedure itself. The procedure is 
rather long-lasting — in case of our center it usually takes about 200 minutes to perform a full 
procedure. It obviously depends on the conditions, location and, mostly, the size of the UF. 
Our center does not fall behind other centers in the world and the duration of the sonication 
performed in here is similar to that in other countries [51]. Regrettably, treatment duration is 
not its advantage regarding the fact that it involves the exclusion of the MRI device from its 
everyday use in diagnostic testing. It requires further steps aiming at the improvement of the 
quality and shortening the procedure. Seemingly, it is worth testing various uterotonics which 
shorten procedure duration [37]. 
In regards to the symptomatology of UFs in the present study group, the dominant 
manifestations were ones typical of this medical condition, i.e., menorrhagia, dysmenorrhea, 
dyspareunia, voiding and gastrointestinal symptoms. No significant differences were observed 
between the groups of patients qualified for and disqualified from MR-HIFU. The aim of 
MR-HIFU treatment of UFs was verified by the reduction in the clinical manifestations and 
NPV parameter [52]. NPV reflects the ratio of non-perfused UF volume after contrast 
enhancement to the total volume expressed as a percentage [52, 53]. According to available 
data, NPV values are commonly consistent with symptom resolution [54]. The mean NPV 
result of 71% in the present group of patients who underwent treatment may be referred to as 
good. It correlated with the resolution of symptoms and the reduction in UF volume at post-
treatment follow-up. We already mentioned in the results section that the study showed no 
correlation between age, BMI and NPV, which is also important from the clinical point of 
view. It is currently believed that the reduction of symptoms is the most important aim of 
MR-HIFU. During the follow-up visits at three and six months, the majority of patients 
assessed their QoL as ‘improved’. The respective percentages were 61% as ‘improved’ and 
8% as ‘highly improved’ after three months and 53% and 23%, respectively, after six months 
post-treatment. Similar results were presented in the recent meta-analysis by Verpalen et al. 
(2019) who reported the mean symptom reduction at 12-months at 59.9% and lesion volume 
shrinkage at 37.7% [53]. Moreover, MR-HIFU proved to be effective as regards the sexuality 
of patients with UFs, as the method was associated with similar post-procedure sexual 
function scores and re-intervention rates compared to myomectomy [30]. In our opinion the 
results may be assessed as more than promising. Therefore, the method should be more 
widely promoted in patients with symptomatic UFs, especially those who rule out the 
possibility of undergoing a surgery.   
The economic dimension of the procedure is also an important aspect. The payback 
time of such an investment (equipment purchase and personnel training) with the assumption 
of performing three procedures weekly with a well exploited MRI device in the diagnostic 
work-up is approximately seven-years. It is of significance to provide a high level of 
assistance services due to the very specialized and unique type of the device and 
individualized software. High service costs are necessary because of a high risk of long-
lasting downtime resulting in remarkable economic loss [3]. In this place it is also worth 
noting that personnel training is essential for adequate cost planning, as it is possible only in 
few centers worldwide and may constitute a substantial financial burden. Therefore, a full 
training option and the assistance of a company providing an MR-HIFU device should be 
comprised. However, system optimization may include the use of the device beyond the 
standard working hours due to the elective nature of the procedures. It also translates into 
increased income.  
The cost of laparoscopic myomectomy covered by the Polish National Health Fund is 
still highly underestimated. The calculations include no cost of the treatment of 
complications, medications and high social cost for the system. This means that the real cost 
of operative procedures is increased by sick leave, no tax paid for the duration of sick leave, 
and the cost of substitution at work. A prolonged stay of a patient with complications in the 
hospital, including intensive care unit, is an unpredictable and high cost, which is rare in 
terms of statistical data, but sometimes inevitable. It needs to be remembered that numerous 
centers still offer the classic modality of UF treatment, i.e., open surgery, in which the cost of 
treatment increases due to longer hospitalization and higher complication rates. In this model 
the benefits of ultrasound thermal ablation are clearly visible, not only because of the cost of 
medications and care, but also due to diminished suffering, stress and the risk of 
complications. 
The innovative character of the issue and the size of the study population, which 
seems to be rather large for Polish conditions, are the advantages of the present publication. 
MR-HIFU procedures may still be considered pioneering ones due to the low availability of 
the device, trained personnel and the low awareness of practicing physicians of the 
availability of minimally invasive treatment with HIFU (MRI- or ultrasound-guided) or UAE 
in Poland. The activity of new centers should be viewed as a huge success due to the 
invariably high costs. Researchers should also focus on analyzing treatment results and 
standardizing procedures for the region/country, which will improve the therapy outcomes 
and may make such therapies available as standard procedures for selected patients. 
Additionally, we believe it is important to encourage researchers to participate in multicenter 
cooperation to compare various methods such as MR-HIFU vs ultrasound-guided HIFU, 
HIFU vs myomectomy, or HIFU vs UAE. Each publication should include the specification 
of some visible limitations. In our viewpoint, the limitation of the present paper results from 
the use of a non-validated simple QoL scale instead of a standardized form, e.g. ‘The Uterine 
Fibroid Symptom and Quality of Life (UFS-QOL)’ which is very common [55]. Undoubtedly, 
it lowers the quality of data obtained and in numerous aspects it may hinder a more precise 
interpretation or comparisons. In this case the present authors aimed at achieving as many 
results as possible, to achieve the maximum follow-up rate possible and cover almost the 
whole study population. It is widely known that the percentage is always reduced in case of 
more complicated forms. However, the present authors are planning to use previously 
evaluated scales in the subsequent publications so that the results may be used in multicenter 
studies and meta-analyses. 
 
CONCLUSIONS 
 MR-HIFU therapy is associated with good clinical outcomes in patients with 
symptomatic UFs. The method facilitates a marked symptom reduction and, in many cases, 
diminishing UF volume.    
The key issue of the optimization of treatment outcomes is appropriate patient 
qualification and the experienced team of gynecologists and radiologists who implement 
optimal qualification and treatment.  
The presented five-year outcomes as regards our experience in the MR-HIFU therapy 
of patients with UFs indicate that the method offers an attractive alternative to traditional 
methods of UF treatment and patients should be informed about its availability.  
The non-invasiveness of the procedure, lack of social costs connected with sick leave 
or possible complications make the ultrasound thermal ablation of UFs worth considering as a 
part of a wide range of benefits despite the high price of the device.      
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Figure 1. UF prior to thermal ablation (A) and after thermal ablation with visible necrosis (B) 
 
 
Figure 2. The difference between uterine fibroids volumes assessed with ultrasound and 
magnetic resonance imaging in groups in which MR-HIFU was and was not performed; SD — 
standard deviation; MRI — magnetic resonance imaging; MR-HIFU — magnetic resonance-
guided high-intensity ultrasound 
 






Figure 4. The quality of life in patients who underwent magnetic resonance-guided high-
intensity ultrasound at three and six months post-treatment 
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